Editing Prostate Cancer: Management of Locally Advanced Prostate Cancer (section)

====== Southwest Oncology Group (SWOG) 8794 ======
* Initiated in 1987
* Population: 431 men with pT3 prostate cancer and/or positive surgical margins; ≈two thirds had undetectable PSA at randomization.
* Randomized to adjuvant RT vs. observation
* Results:
** Median follow-up of 12.5 months
** Median metastasis-free survival was significantly longer in the adjuvant radiation therapy arm compared to the salvage group (14.7 vs.12.9 years) in the salvage group.
** Overall survival was significantly longer in the adjuvant therapy group compared to the salvage arm (15.2 vs. 13.3 years). The number of men with pathologic T3 disease who must be treated with adjuvant radiotherapy to prevent 1 death at a median follow-up of 12.6 years was 9.1 patients.
* Interpretation: Adjuvant radiotherapy within 18 weeks after radical prostatectomy in patients with T3N0M0 prostate cancer significantly reduces the risk for PSA recurrence, metastasis, and need for hormonal therapy and increases overall survival.
*[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3510761/ Thompson, Ian M., et al.] "Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial." ''The Journal of urology'' 181.3 (2009): 956-962.